A population PK–PD model of YH4808, a novel P‐CAB, and intragastric pH that incorporated negative feedback by increased intragastric pH onto the systemic exposure to YH4808

YH4808 is a novel potassium‐competitive acid blocker that is under clinical development to treat patients with gastroesophageal reflux disease and peptic ulcer diseases. In this study, the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of YH4808 were modeled in healthy male volunteers who re...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Tae Kyu, Lee, Hyun A., Lee, Kyeong‐Ryoon, Jang, Seong Bok, Yu, Kyung‐Sang, Lee, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469698/
https://www.ncbi.nlm.nih.gov/pubmed/35748058
http://dx.doi.org/10.1002/psp4.12839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469698/
https://www.ncbi.nlm.nih.gov/pubmed/35748058
http://dx.doi.org/10.1002/psp4.12839

Ejemplares similares